Taurineと本態性高血圧症の血小板凝集能(B 臨床的研究)

概要

論文の詳細を見る
We studied the effect of taurine on platelet aggregation in normals and essential hypertensives. Platelet aggregation was performed with ADP 2.3 μM (final concentration) in 28 normals, 23 treated essential hypertensives and 11 untreated essential hypertensives. ADP-induced platelet aggregation was significantly greater in untreated essential hypertensives than in normals (P<0.01 ). To evaluate the anti-aggregatory effect of taurine, ADP-induced aggregation was performed after preincubation of platelet-rich plasma with taurine 25 mM (final concentration) in the same subjects. Addition of taurine significantly inhibited (P<0.01) ADP-induced aggregation in normals and treated essential hypertensives, whereas did not in untreated essential hypertensives. This antiaggregatory potency of taurine was similar to trimetadizine 0.05 mg/ml (final concentration) in normals. Thus, it is concluded that taurine has an obvious antiaggregatory potency in vitro, and that the platelet sensitivity to taurine is different between normals and essential hypertensives. The results suggest that there may be some abnormalities in the membrance or inner platelet structure of essential hypertensives and that taurine may be an important factor in determining the activity of plate-et, so that taurine is useful as a platelet antiaggregatory agent in ischemic heart disease and cerebral thrombosis.
近畿大学の論文
1983-12-30